eligibility_summary
Adults >18, ECOG 0-1, RRMM after ≥3 lines with prior IMiD, PI, and anti-CD38 failure, measurable disease, adequate marrow/organ function (no transfusion or growth factor within 7 d), willing for bone marrow biopsy. Exclude: noncompliance, amyloidosis, plasma cell leukemia, Waldenstrom, MDS, recent therapy (≤21 d/5 half-lives), investigational ≤4 w, anti-CD38 ≤28 d, >Grade 1 tox (except G2 neuropathy, alopecia, irreversible), large-field RT ≤28 d, auto-SCT ≤180 d, any allo-SCT.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05908396 tested IGM-2644, a first-in-human, IV, engineered bispecific IgM antibody (T‑cell engager) that binds CD38 on myeloma cells and CD3 on T cells. Mechanism: redirects T cells to CD38+ malignant plasma cells to induce T‑cell–dependent cellular cytotoxicity (TDCC) and also triggers complement‑dependent cytotoxicity (CDC). Targets/pathways: CD38 (myeloma), CD3 (T cells), T‑cell cytotoxicity and complement activation. Status: Phase 1, terminated (company decision).